At the moment a novel therapeutic approach against prostate cancer is tested in a clinical trial [65], tg coupled to a chemical cage that is specially cleaved of by prostate specific membrane antigen (PSMA) a prostate specific protease [66]. This evidence concerns the gene FOLH1 and prostate carcinoma.